Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status Prescription; Discontinued
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 68071-4215; 23155-019; 70518-1829; 50090-0086; 49964-0018; 43353-495; 63629-5688; 70518-0185; 51927-0054; 51927-0081; 0591-0796; 0013-0101; 59762-0104; 38779-0176; 0013-0102; 50268-730; 59116-0632; 62705-0222; 62991-2704; 57294-021; 59116-0631; 71610-577; 59762-5000; 59116-0633; 59116-0630; 62135-960; 51552-1044; 50090-2013; 49452-7523; 68022-7065; 70518-2342
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.029703%Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.0020.015197%
Abdominal pain upper07.01.05.0030.008980%
Abortion spontaneous18.01.04.001--Not Available
Acute febrile neutrophilic dermatosis01.02.01.006; 23.03.03.0330.002072%Not Available
Acute hepatic failure09.01.03.0010.000901%Not Available
Acute myocardial infarction02.02.02.001; 24.04.04.001--Not Available
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.0010.002763%Not Available
Alanine aminotransferase increased13.03.01.0030.007598%
Allergic myocarditis02.04.03.003; 10.01.03.039--Not Available
Alopecia23.02.02.001--
Alveolitis22.01.01.0010.004145%Not Available
Alveolitis allergic10.01.03.008; 22.01.01.0020.001382%Not Available
Anaemia01.03.02.001--
Anaemia Heinz body01.04.01.001--Not Available
Anaemia macrocytic01.03.02.002; 14.12.01.002--Not Available
Anaemia megaloblastic01.03.02.003; 14.12.01.003--Not Available
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema10.01.05.009; 23.04.01.001--Not Available
Ankylosing spondylitis10.04.04.004; 15.01.09.0010.004145%Not Available
Anuria20.01.03.002--Not Available
Anxiety19.06.02.002--
Aplasia pure red cell01.03.03.001; 10.02.01.0030.002072%Not Available
Aplastic anaemia01.03.03.002--Not Available
Arthralgia15.01.02.0010.021414%
The 1th Page    1 2 3 4 5    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene